XML 41 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Segment Information (Tables)
6 Months Ended
Oct. 31, 2013
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
The following tables summarize, for the periods indicated, operating results by business segment (in thousands):   
 
Three Months Ended October 31, 2013
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
 
Net revenue
 
$
623
 
$
1,760
 
$
-
 
$
2,383
 
Direct cost of services
 
 
(726)
 
 
(696)
 
 
-
 
 
(1,422)
 
Sales and marketing costs
 
 
(423)
 
 
(213)
 
 
-
 
 
(636)
 
Other operating expenses
 
 
-
 
 
(673)
 
 
(877)
 
 
(1,550)
 
Stock- based compensation expense (1)
 
 
-
 
 
 
 
 
(476)
 
 
(476)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(526)
 
$
178
 
$
(1,353)
 
$
(1,701)
 
 
Three Months Ended October 31, 2012
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
 
Net revenue
 
$
459
 
$
999
 
$
-
 
$
1,458
 
Direct cost of services
 
 
(576)
 
 
(471)
 
 
-
 
 
(1,047)
 
Sales and marketing costs
 
 
(378)
 
 
(241)
 
 
-
 
 
(619)
 
Other operating expenses
 
 
-
 
 
(433)
 
 
(651)
 
 
(1,084)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(624)
 
 
(624)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(495)
 
$
(146)
 
$
(1,275)
 
$
(1,916)
 
 
Six Months Ended October 31, 2013
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
 
Net revenue
 
$
1,245
 
$
4,158
 
$
-
 
$
5,403
 
Direct cost of services
 
 
(1,470)
 
 
(1,566)
 
 
-
 
 
(3,036)
 
Sales and marketing costs
 
 
(754)
 
 
(460)
 
 
-
 
 
(1,214)
 
Other operating expenses
 
 
-
 
 
(1,063)
 
 
(1,534)
 
 
(2,597)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(1,028)
 
 
(1,028)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(979)
 
$
1,069
 
$
(2,562)
 
$
(2,472)
 
 
Six Months Ended October 31, 2012
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
 
Net revenue
 
$
1,377
 
$
2,187
 
$
-
 
$
3,564
 
Direct cost of services
 
 
(1,293)
 
 
(1,162)
 
 
-
 
 
(2,455)
 
Sales and marketing costs
 
 
(814)
 
 
(432)
 
 
-
 
 
(1,246)
 
Other operating expenses
 
 
-
 
 
(794)
 
 
(1,221)
 
 
(2,015)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(1,364)
 
 
(1,364)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(730)
 
$
(201)
 
$
(2,585)
 
$
(3,516)
 
 
(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.